Antibiotika-Therapie bei Patienten mit Fieber und Neutropenie

Literatur
1 Ahn S, Lee YS, Lim KS et al. Adding procalcitonin to the MASCC risk-index score could improve risk stratification of patients with febrile neutropenia. Support Care Cancer 2013; Mar 22 [Epub ahead of print]
2 André S, Taboulet P, Elie C et al. Febrile neutropenia in French emergency departments: results of a prospective multicentre survey. Crit Care 2010; 14: R68
3 Arnan M, Gudiol C, Calatayud L et al. Risk factors for, and clinical relevance of, faecal extended-spectrum β-lactamase producing Escherichia coli (ESBL-EC) carriage in neutropenic patients with haematological malignancies. Eur J Clin Microbiol Infect Dis 2011; 30: 355-360
4 Clarke RT, Warnick J, Stretton K et al. Improving the immediate management of neutropenic sepsis in the UK: lessons from a national audit. Br J Haematol 2011; 153: 773-779
5 Cornejo-Juárez P, Pérez-Jiménez C, Silva-Sánchez J et al. Molecular analysis and risk factors for Escherichia coli producing extended-spectrum β-lactamase bloodstream infection in hematological malignancies. PLoS One 2012; 7: e35780
6 4th European Conference on Infections in Leukemia, ECIL 4 2011. Bacterial resistance in haematology. http://www.eortc.org/sites/default/files/ECIL%204%202011%20Bacterial%20resistance%20in%20Haematology.pdf (letzter Zugriff 15.5.2013)
7 Flowers CR, Seidenfeld J, Bow EJ et al. Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 2013; 31: 794-810
8 Freifeld AG, Bow EJ, Sepkowitz KA et al. Infectious Diseases Society of America. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer. 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 2011; 52: e56-93
9 Gafter-Gvili A, Fraser A, Paul M et al. Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy. . Cochrane Database Syst Rev 2012; Jan 18; (01) CD004386
10 Hendricks AM, Loggers ET, Talcott JA. Costs of home versus inpatient treatment for fever and neutropenia: analysis of a multicenter randomized trial. J Clin Oncol 2011; 29: 3984-3989
11 Juutilainen A, Hämäläinen S, Pulkki K et al. Biomarkers for bacteremia and severe sepsis in hematological patients with neutropenic fever: multivariate logistic regression analysis and factor analysis. Leuk Lymphoma 2011; 52: 2349-2355
12 Kern WV, Marchetti O, Drgona L et al. Oral antibiotics for fever in low-risk neutropenic patients with cancer: a double-blind, randomized, multicenter trial comparing single daily moxifloxacin with twice daily ciprofloxacin plus amoxicillin/clavulanic acid combination therapy – EORTC Infectious Diseases Group trial XV. J Clin Oncol 2013; 31: 1149-1156
13 Kim SH, Kwon JC, Choi SM et al. Escherichia coli and Klebsiella pneumoniae bacteremia in patients with neutropenic fever: factors associated with extended-spectrum β-lactamase production and its impact on outcome. Ann Hematol 2013; 92: 533-541
14 Klastersky J, Paesmans M. The Multinational Association for Supportive Care in Cancer (MASCC) risk index score: 10 years of use for identifying low-risk febrile neutropenic cancer patients. Support Care Cancer 2013; 21: 1487-1495
15 Lathia N, Isogai PK, Walker SE et al. Eliciting patients' preferences for outpatient treatment of febrile neutropenia: a discrete choice experiment. Support Care Cancer 2013; 21: 245-251
16 Lin CH, Yao M, Hsu SC et al. Soluble triggering receptor expressed on myeloid cells-1 as an infection marker for patients with neutropenic fever. Crit Care Med 2011; 39: 993-999
17 Lingaratnam S, Thursky KA, Slavin MA et al. The disease and economic burden of neutropenic fever in adult patients in Australian cancer treatment centres 2008: analysis of the Victorian Admitted Episodes Dataset. Intern Med J 2011; 41: 121-129
18 Lingaratnam S, Worth LJ, Slavin MA et al. A cost analysis of febrile neutropenia management in Australia: ambulatory v. in-hospital treatment. Aust Health Rev 2011; 35: 491-500
19 Liss BJ, Vehreschild JJ, Cornely OA et al. Intestinal colonisation and blood stream infections due to vancomycin-resistant enterococci (VRE) and extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBLE) in patients with haematological and oncological malignancies. Infection 2012; 40: 613-619
20 Lodahl D, Schrøder H. Procalcitonin adds to diagnosis, but does not reduce initial antibiotics in febrile neutropenic children. Dan Med Bull 2011; 58: A4233
21 Miedema KG, de Bont ES, Elferink RF et al. The diagnostic value of CRP, IL-8, PCT, and sTREM-1 in the detection of bacterial infections in pediatric oncology patients with febrile neutropenia. Support Care Cancer 2011; 19: 1593-600
22 Montassier E, Batard E, Gastinne T et al. Recent changes in bacteremia in patients with cancer. Eur J Clin Microbiol Infect Dis 2013; Jan 25. [Epub ahead of print]
23 Neumann S, Krause SW, Maschmeyer G et al. Infectious Diseases Working Party (AGIHO); German Society of Hematology and Oncology (DGHO). Primary prophylaxis of bacterial infections and Pneumocystis jirovecii pneumonia in patients with hematological malignancies and solid tumors: guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 2013; 92: 433-442
24 Ram R, Farbman L, Leibovici L et al. Characteristics of initial compared with subsequent bacterial infections among hospitalised haemato-oncological patients. Int J Antimicrob Agents 2012; 40: 123-126
25 Robinson JO, Lamoth F, Bally F et al. Monitoring procalcitonin in febrile neutropenia: what is its utility for initial diagnosis of infection and reassessment in persistent fever?. PLoS One 2011; 6: e18886
26 Schelenz S, Giles D, Abdallah S. Epidemiology, management and economic impact of febrile neutropenia in oncology patients receiving routine care at a regional UK cancer centre. Ann Oncol 2012; 23: 1889-1893
27 Sung L, Alibhai SM, Ethier MC et al. Discrete choice experiment produced estimates of acceptable risks of therapeutic options in cancer patients with febrile neutropenia. J Clin Epidemiol 2012; 65: 627-34
28 Talcott JA, Yeap BY, Clark JA et al. Safety of early discharge for low-risk patients with febrile neutropenia: a multicenter randomized controlled trial. J Clin Oncol 2011; 29: 3977-3983
29 Wright JD, Neugut AI, Ananth CV et al. Deviations from guideline-based therapy for febrile neutropenia in cancer patients and their effect on outcomes. JAMA Intern Med 2013; 173: 559-568